COLORADO SPRINGS, Colo.,
July 31, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, is pleased to announce that it has commenced
production of multiple strains of cannabis and European Union
certified hemp varieties to initiate scientific research to select
the best strains for development of proprietary formulations for
clinical drug development to bring the cannabis formulations to
market for critical ailments such as cancer and neurological
disorders.
Mr. Mario S. Lap, Director and
President of European Operations, stated, "Cannabis Science intends
to leverage its team's expertise to create a framework for research
and clinical testing. We are excited to report further development
and progress as we proceed forward."
The facilities are located in the Alicante region of
Spain, and the Company is working
with a local partner to initiate an agricultural program, to
prepare GMP production and to start building the research framework
to conduct scientific testing of extracts and the active
constituents contained in the cannabis plant with the objective of
developing selected formulations for clinical use.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.